Pākuʻi Palmitoylethanolamide - Pehea e hana ai ka PEA no ka ʻeha?

Palmitoylethanolamide (PEA).

Ua hōʻike ʻia ua ʻae ʻia ka Food and Drug Administration e waiho i kahi noi no kahi hoʻokolohua hoʻokolohua e mālama iā COVID-19 ma o ka hoʻohana ʻana i kahi lāʻau synthetic e hoʻohālike i ka hana o kahi mole i loaʻa i ka mariuana.

ʻO ka lāʻau synthetic, i kapa ʻia ʻo ultrametronazone palmitoylethanolamide (micro PEA), manaʻo ʻia e hana ma ke ʻano he anti-inflammatory. ʻO Palmitoylethanolamide (PEA) kahi "kahi waikawa momona kūlohelohe" e like me ka endocannabinoid, kekahi o nā mole i loaʻa i ka cannabis ma nā pahuhopu CB2. Manaʻo ʻia nā CB2 receptors e hoʻololi i ka luhi a me ka ʻeha ma ke kino o ke kanaka.

Ma muli o ka [micro PEA] i hoʻohana ʻia ma ʻEulopa no 20 mau makahiki, ua ʻākoakoa kekahi poʻe lawelawe mālama ola ʻItalia i ka hoʻohana ʻana o micro PEA e mālama i nā maʻi COVID-19 a ke ʻike nei lākou i kahi kūleʻa

Kuhi ʻia ʻo COVID-19 koʻikoʻi e kahi pane hoʻāla nui exuberant i alakaʻi ʻia i kahi ʻino cytokine. "ʻAʻole ka micro PEA ka mea pepehi kanaka, akā manaʻoʻiʻo lākou hiki ke hoʻoliʻiliʻi i kēlā pane pale, hiki ke make.

He aha ka Palmitoylethanolamide (PEA)?

ʻO Palmitoylethanolamide (PEA) he lipid e kū maoli ana i loko o ko mākou kino i ka māhele o ka momona amide. ʻO ia kahi mea he lipid endogenous. Hoʻopuka maoli ʻia ʻo PEA i nā mea kanu a me nā holoholona.

Hiki ke loaʻa iā Palmitoylethanolamide (PEA) i ka meaʻai e like me ka waiū, nā pī soy, nā māla māla, lecithin soy, kaʻiʻo, nā hua manu a me nā pī.

ʻO ka mea lanakila Nobel Prize ʻo Levi-Montalcini i hoʻomaopopo iā Palmitoylethanolamide (PEA) ma ke ʻano he mole kūlohelohe, e wehewehe ana i kona waiwai i ka mālama ʻana i nā maʻi maʻi a me nā ʻeha. Ma hope o kāna loaʻa ʻana, ua lawe ʻia he haneli mau noiʻi ʻepekema e hōʻike he maikaʻi a palekana hoʻi e hoʻohana. Ua wehewehe ʻia ʻo Palmitoylethanolamide (PEA) i loko o nā palapala ʻepekema a painkiller kūlohelohe.

Nā pōmaikaʻi o Palmitoylethanolamide - He aha ka Palmitoylethanolamide i hoʻohana ʻia no?

ʻO Palmitoylethanolamide (PEA) kahi amide acid amide a hoʻohui ʻia a hana i loko o ko mākou kino no ka hoʻoponopono ʻana i nā hana like ʻole. ʻO ia kahi amide acid fatally acid momona, no ka papa o nā agonists nukleona. Palmitoylethanolamide (PEA) ʻike maoli ʻia i loko o ka nui o nā holoholona holoholona hoʻoheheʻe, a me nā hoʻokolohua olakino.

He painkiller kūlohelohe ia a hiki ke hoʻohana ʻia no ka ʻeha mau loa a me ka pehu. Hoʻomaopopo pū kekahi i nā hopena maikaʻi ʻē aʻe e like me ka neuropathic ache, fibromyalgia, kekahi sclerosis, ʻeha pinepine hou, nā maʻi o ka hanu hanu, a me nā maʻi ʻē aʻe he nui.

ʻO kekahi o nā pono o ka palmitoylethanolamide i hōʻike ʻia;

i Kākoʻo i ke olakino lolo

Loaʻa nā Palmitoylethanolamide i ka hoʻonui ʻana i ke olakino lolo e pili ana i kona hiki ke hakakā i ka maʻi neural a hoʻolaʻa pū nō hoʻi i nā neural cell ola. Hoʻomaopopo pinepine ʻia kēia me ka poʻe e loaʻa ana i nā maʻi neurodegenerative a me nā hōʻeha.

ʻO kahi laʻana, i kahi noiʻi o 250 mau kānaka e ʻeha nei i ka maʻi hahau, loaʻa ʻia kahi waihona palmitoylethanolamide i lawelawe ʻia me ka luteolin e hoʻonui ai i ka hoʻōla hou ʻana. Ua loaʻa ʻo PEA e hoʻomaikaʻi i ka hoʻomanaʻo, ke olakino lolo āpau a me ka hana o kēlā me kēia lā. Ua ʻike ʻia kēia mau hopena o ka palmitoylethanolamide kaola 30 mau lā ma hope o ka hoʻoliʻiliʻi a hoʻonui ʻia ma mua o hoʻokahi mahina hou.

ii. Hōʻoluʻolu mai ka nui o ka ʻeha a me ka mumū

Hāʻawi nā ʻepekema ʻepekema ākea i nā maʻi palmitoylethanolamide e hoʻomaha ana i nā waiwai. E like me ka mea e hōʻike ai, ʻo ka palmitoylethanolamide e hāʻawi i ka hōʻoluʻolu o nā ʻeha i nā ʻano like ʻeha a me ka ʻeha. ʻO kekahi mau noiʻi e hōʻike ana i nā hōʻola hōʻeha ʻeha palmitoylethanolamide;

I kahi noiʻi e pili ana i nā holoholona, pākuʻi palmitoylethanolamide Loaʻa me ka quercetin e hāʻawi i ke kōkua mai ka ʻeha hui a me ka hoʻomaikaʻi ʻana i ka hana hui a me ka pale ʻana o ka cartilage mai ka pohō.

Ke hōʻike nei kekahi mau noiʻina mua e hiki i ka PEA ke kōkua i ka hōʻemi ʻana i nā hōʻehaʻeha o nā nerve ma nā mea maʻi maʻi maʻi (diabetes neuropathy).

Ma kekahi noiʻi me nā kānaka he 12, ʻo kahi maʻi palmitoylethanolamide o 300 a me 1,200 mg / lā i hāʻawi ʻia no 3 a 8 mau pule i ʻike e hoʻohaʻahaʻa i ka ulu o nā maʻi a me ka neuropathic hōʻeha.

ʻO kahi hōʻike o nā maʻi 80 e loaʻa ana i ka maʻi Fibromyalgia i ʻike i ka PEA ma kahi o nā lāʻau ʻē aʻe no ka maʻi hiki e hoʻohaʻahaʻa i ka ʻeha.

Eia kekahi, ua hōʻike kekahi mau haʻawina hou i ka palmitoylethanolamide pain relief hiki ke hōʻoluʻolu i ka maʻi pelvic, sciatic pain, back back, ʻeha ʻeha i waena o kekahi.

iii. Kōkua e hōʻemi i nā ʻōuli o ke kaumaha

Hoʻololi kūʻokoʻa ʻo PEA i nā mea loaʻa i ke kuleana no ka naʻau. Hōʻike kekahi mau noiʻi i ka palmitoylethanolamide hopohopo i ke kōkua ma ke ʻano he kī nui i ka hakakā ʻana i ke kaumaha.

Ma ka noiʻi o nā mea maʻi 58 me ke kaumaha, palmitoylethanolamide supplementation ma 1200 mg / lā me ka lāʻau antidepressant (citalopram) i lawelawe ʻia no nā hebedoma 6 ua loaʻa hou ka hoʻomaikaʻi hou ʻana i ka ʻano a me nā hōʻailona kaumaha kaumaha.

iv. Hoʻomaha ia i ke anuanu maʻamau

Loaʻa nā Palmitoylethanolamide i ka hoʻopili ʻana i nā anuanu maʻamau i loko o kona hiki ke luku i ka virus i kuleana no ke anuanu (influenza virus). ʻOiai pīhoihoi, hele pinepine ka anu a maʻamau i ka hapanui o nā kānaka āpau a me ka poʻe me ka pale ʻana.

Ke hōʻike nei me kahi pūʻali koa 900 e hōʻike ana he ka maʻi palmitoylethanolamide o 1200 mg i kēlā me kēia lā ka hoʻohaʻahaʻa i ka manawa i lawe ʻia e ka mea hele mai e hoʻōla mai ka malulu a me nā hōʻailona pū kekahi e like me ke poʻo, ke aʻala a me nā ʻehaʻeha.

v. Hoʻohaʻahaʻa i nā ʻōuli o ka insular (mau) sclerosis

Me nā mau waiwai anti-inflammatory i hōʻike ʻia iā palmitoylethanolamide, ʻaʻohe mea maopopo loa ʻo PEA no ka mālama ʻana i ka sclerosis lehulehu.

Ma kahi noiʻi o nā mea maʻi 29 e loaʻa ana i ka sclerosis holomua holomua, ua hoʻohui ʻo PEA i ka maʻa maʻamau o interferon IFN-β1a i loaʻa e hoʻohaʻahaʻa i ka ʻeha me ka hoʻomaikaʻi ʻana i ka maikaʻi o nā mea maʻi.

vi. Hoʻomaikaʻi ʻo Palmitoylethanolamide i ka metabolism

Hiki iā Palmitoylethanolamide (PEA) ke hoʻopaʻa iā PPAR- α, kahi mea loaʻa i ka ʻepekema, ka makemake, ka pohō a me nā momona momona. Ke hoʻonāukiuki ʻia ka receptor PPAR iā ʻoe e ʻike i nā pae ikehu kiʻekiʻe e kōkua ai i ke kino e kuni i nā momona hou aʻe i nā hana no laila e lilo ana kou kaupaona.

vii. Hiki i ka Palmitoylethanolamide ke hoʻohaʻahaʻa i kou makemake

Hōʻike ʻia ka lilo nui o Palmitoylethanolamide i kona hiki ke hoʻoikaika i kou makemake. Hoʻohālike i ka hoʻomaikaʻi ʻana i ka metabolism, ke hana ʻia ka mea hoʻokipa PPAR- α e alakaʻi ana i kahi manaʻo o ka piha piha i ka wā e ʻai ai ʻoe e kōkua iā ʻoe e mālama i ka nui o nā calorie i hoʻopau.

Eia kekahi, ʻike ʻia ʻo PEA me kahi ethanolamides momona momona e hana i ka hana koʻikoʻi ma ka hānai ʻana i ka hana. I ka noiʻi ʻana o nā mea ʻai overiectomized me ka loaʻa ʻana o ka paona nui, ʻo ka hoʻonui ʻana ʻo PEA ma kahi o 30 mg / kg kino kino no nā wiki 5 i ʻike ʻia e hoʻohaʻahaʻa nui i kā lākou ʻai, ka momona momona a ma ka hopena o ke kino o ke kino.

viii. Palmitoylethanolamide hopena anti-inflammatory i ka hoʻoikaika kino

ʻIke paha kekahi i ka ʻeha a me ka mumū i ka wā a ma hope o ka hoʻomaʻamaʻa ma muli o ke kaumaha nui. ʻĀ, hiki i ka pākuʻi PEA ke pale aku i kēia me ka hoʻoulu ʻana i ka hana anti-inflammatory o ka mea loaʻa iā PPAR- α. Hiki i ka Palmitoylethanolamide ke kāohi i ka hoʻokuʻu ʻia ʻana o nā enzymes inflammatory i loko o ka e nā aʻa kanaka.

ʻO wai e lawe i kahi hoʻohui o Palmitoylethanolamide (PEA)?

Hoʻopau ka Palmitoylethanolamide (PEA) i nā mea āpau no ka ʻehaʻeha a i ʻole ka hoʻoweliweli a me kekahi mea makemake hou i ke kaupaona ʻana ma ka lāʻau a inā ʻaʻole paha. Ua ʻike ʻia ka PEA e hoʻoikaika i ka pono o nā lāʻau ʻē aʻe. He koho ia no ka poʻe i ʻike ʻole i ka hōʻoluʻolu ma ka hoʻohana ʻana i nā mea pepehi maka i kauoha ʻia.

Palmitoylethanolamide hōʻoluʻolu He kūlana maikaʻi loa ia no ka makaʻu o ke kaumaha a i ʻole ka ʻeha ʻana i ke kaumaha e lawe iā PEA no.

Eia nō kekahi, e ʻohi hou i kekahi i ka PEA mai nā mea hoʻohui mai ka ʻimi ʻana o ka mea hana i nā formulat e hoʻonui ai i ka bioavailability o ka palmitoylethanolamide i loko o kou kino.

He aha nā PEA i lawe ʻia mai?

Hana maoli ʻia ʻo PEA i loko o ko mākou kino a nā holoholona a me nā mea kanu nō hoʻi. Eia nō naʻe, no ka poʻe me ka ʻehaʻeha a me nā hōʻeha ʻana, e hele mai ana ka PEA i ka nui o ka nui o ka manawa no ka pono no ka lako o PEA.

Hiki ke loaʻa iā Palmitoylethanolamide mai nā kumu waiwai i waiwai i nā protein e like me ka waiū, kaʻiʻo, nā pī soy, lecithin soy, nā pī a me nā pī māla a me nā mea ʻē aʻe. Eia nō naʻe, ua liʻiliʻi ka PEA i loaʻa mai nā kumuwaiwai. Hana kēia i ka palmitoylethanolamide nui i ka hana e pono ai e pono ai kēia papaʻai.

Kiʻi kiʻekiʻe ʻo PEA iā ʻoe?

Hiki iā Phenethylamine lāua ʻo Palmitoylethanolamide ke kāhea iā PEA, akā ʻokoʻa nā huahana like ʻole.

ʻO Phenethylamine (PEA) kahi hui kūlohelohe, alkaloid monoamine maoli, a me ka amine trace, e hana nei ma ke ʻano he stimulant ʻōnaehana waena i loko o nā kānaka. Hoʻoulu ʻo Phenethylamine i ke kino e hana i kekahi mau kemika e pāʻani i ke kaumaha a me nā kūlana psychiatric ʻē aʻe.

Lawe ʻia i nā koina o 500mg-1.5g no kēlā me kēia lā, kēlā me kēia mau hola, hāʻawi ʻo PEA i ka mea hoʻohana i ka euphoria, ka ikehu, hoʻonāukiuki, a me ka maikaʻi holoʻokoʻa.

Eia naʻe, e ʻoluʻolu e hoʻomaopopo iā Phenethylamine (PEA) ʻaʻole Palmitoylethanolamide (PEA). ʻAʻole ʻae ʻia e ka FDA nā mea kōkua Phenethylamine no ka hoʻohana olakino. ʻO Palmitoylethanolamide (PEA) kahi mea kūlohelohe i hana ʻia e ke kino; maikaʻi loa a palekana hoʻi e hoʻohana ma ke ʻano he mea kōkua no ka ʻeha a me ka mumū.

Ua palekana anei ka PEAsupplement?

ʻO Palmitoylethanolamide (PEA) kahi mea kūlohelohe i hana ʻia e ke kino; he mea maikaʻi loa a palekana hoʻi e hoʻohana i mea hoʻohui no ka ʻeha a me ka mumū. ʻAʻole i hōʻike ʻia nā hopena ʻaoʻao o ka palmitoylethanolamide a ʻaʻole hoʻi i pili pū me nā lāʻau lapaʻau ʻē aʻe.

He aha nā hopena a ka PEA?

ʻAʻohe hopena ʻino a i ʻole hōʻike ʻia nā pilina lāʻau lāʻau i kēia manawa. Hiki ke lawe pū ʻia ʻo Palmitoylethanolamide me nā mea ʻē aʻe. Hoʻonui ia i ka hopena hōʻoluʻolu o nā analgesics kahiko a me nā anti-inflammatories.

Palekana ʻo Palmitoylethanolamide palekana i ka hāpai?

ʻAʻole e hoʻohana ʻia e nā wahine hāpai.

Hiki i ka Palmitoylethanolamide ke kōkua i ke olakino e hoʻoponopono i ka mumū a me ka ʻeha mau.

E lawe wale ʻia ia ma lalo o ka mālama lāʻau.

ʻO Palmitoylethanolamide hapalua ke ola - Pehea ka lōʻihi e hana ai i ka pī?

Hiki ke lawe pū ʻia ʻo Palmitoylethanolamide (PEA) me nā lāʻau ʻeha ʻē aʻe a i ʻole ʻo ia wale nō, e like me ka ʻōlelo aʻoaʻo a kāu mea mālama ola, e kākoʻo ai i ka ʻeha.

ʻO ka maikaʻi no ka hōʻoluʻolu ʻeha ʻo 8 hr

Laulā nā hopena; nā hopena ma waena o 48 hr i kekahi poʻe, akā hoʻohana no 8 mau pule no ka nui o nā hopena, hiki ke hoʻohana i ka wā lōʻihi no ka ʻeha neurological mau.

Pehea e hana ai ka PEA no ka ʻeha?

Ua hōʻike ʻia kahi noiʻi e loaʻa ana i ka PEA nā anti-inflammatory a me anti-nociceptive a lawe pinepine iā ia e hoʻonui ai i ka pane kūlohelohe o kou kino i ka ʻeha ma ka hoʻoliʻiliʻi ʻana i ka pane o nā pūnaewele ʻōnaehana i hōʻeha ʻia

ʻO Palmitoylethanolamide hana hana ʻole pū kekahi e hoʻohuli i nā hana o kekahi mau mea loaʻa e like me nā mea loaʻa lāʻau cannabinoid. Hoʻoikaika ka PEA i nā mea loaʻa pū kaʻi cannabinoid (CB1 a me CB2) e ka hana ʻana ma ke ʻano he enzyme (FAAH -fatty acid amide hydrolase) pili i ka haki o ka cannabinoid anandamide. ʻO kēia kōkua i ka hāpai ʻana i nā pae o ka anandamide i loko o kā mākou kino, nona ke kuleana no ka hoʻomaha a me ka hakakā ʻana i ka ʻeha.

He aha ka PEA no ka hōʻoluʻolu ʻeha?

ʻO Palmitoylethanolamide (PEA) kahi mea kūlohelohe i hana ʻia e ke kino; he amide acid momona endogenous, no ka papa o nā agonists nukelea, a hiki ke hoʻohana ʻia ma ke ʻano he mea kōkua no ka ʻeha a me ka lāʻau hoʻomā. ʻO ka PEA kahi mole kūlohelohe, palekana, momona momona i hana ʻia i loko o kā mākou kino, e kōkua ana i ke kākoʻo i nā ʻiʻo myelin nerve no ka hana nerve maikaʻi.

ʻO ka PEA kahi waikawa momona e pili ana i nā hana cellular like ʻole i ka mumū a me ka ʻeha mau loa, a ua hōʻike ʻia e loaʻa nā neuroprotective, anti-inflammatory, anti-nociceptive (anti-pain) a me anti-convulsant. Hoʻoemi ia i ka motus gastrointestinal a me ka ulu ʻana o ka maʻi ʻaʻai, a me ka pale ʻana i ka endothelium vascular i ka puʻuwai ischemic. ʻO ka pinepine i ka poʻe me nā maʻi mau, ʻaʻole lawa ke kino o ka PEA, no laila ma ka lawe ʻana i ka PEA e hoʻopiha ai i ka hemahema o ke kino he mea maikaʻi paha ia i ke kōkua ʻana e mālama i kēia mau ʻano.

He anti anti-inflammato paha ʻo Pea?

ʻO Palmitoylethanolamide (PEA) kahi mea hoihoi anti-inflammatory therapeutic waiwai a paʻa paha i ka hoʻohiki maikaʻi loa no ka mālama ʻana i kekahi o nā maʻi pale (auto), e like me ka maʻi ʻōpū a me nā maʻi inflammatory o ka CNS.

Maikaʻi ka pī no ka maʻi kōpaʻa?

Hāʻawi ʻo Palmitoylethanolamide (PEA) i ke keu pono no ka maʻi ʻelua e pili ana i ka hōʻemi ʻana i ka hoʻomohala ʻana a me ka mālama ʻana o ka ʻeha mau akā e kōkua pū hoʻi i ka holomua o ka luku pū ʻia e pili ana me ka maʻi kō.

He aha nā painkillers maikaʻi loa no ka ʻehaʻeha nerve?

ʻO PEA (palmitoylethanolamide) ma kahi o ka makahiki 1970 akā ke kaulana nei ʻo ia ma ke ʻano he agena hou i ka mālama ʻana i ka mumū a me ka ʻeha. ʻAʻole ʻike ʻia nā launa lāʻau a i ʻole ka hopena ʻaoʻao koʻikoʻi.

Ua hōʻike ʻo PEA i ka maikaʻi no ka ʻeha mau o nā ʻano he nui e pili ana i nā ʻano ʻeha he nui, keu hoʻi me ka ʻeha neuropathic (nerve), ʻehaʻeha a me ka ʻeha visceral e like me endometriosis a me interstitial cystitis.

Pehea e hiki ai iaʻu ke mālama i ka ʻehaʻeha ma ka home?

ʻO ka PEA kahi mole mole momona e kōkua i ke kākoʻo i nā uhi nerve myelin no ka hana nerve maikaʻi.

ʻO ka lawa ʻole o nā wikamina mai ka hui B hiki ʻole ke hōʻeha i nā ʻeha nerve, akā hoʻonui pū kekahi ia.

Hiki ke ʻike ʻia kekahi mau hōʻailona maikaʻi ʻole, e like me ke ala hele wobbly, ke kani a me ka ʻū ʻana o nā lima a me nā wāwae, kahi manaʻo me he mea lā ke hele nei kekahi ma ka uea barbed a i ka hulu pulupulu a i ʻole ka helu o ka

nā lima a me nā wāwae.

ʻO ka liʻiliʻi loa o ka huaʻai B1 hiki i ka haunaele i ka hana o nā aʻa a no laila i ka neuropathy a me ka ʻeha o ke aʻalolo. Ke hoʻohui nei i ka wikamina B1, hoʻemi ka ʻeha a hoʻomaikaʻi ke ʻano o ke aʻalolo. Hiki ke lawe pū ʻia ka wikamina B1 me PEA, hāʻawi kēia i ke kākoʻo maikaʻi loa i ka hana o nā ʻalalā, pale i ka ʻeha o ke aʻa a i ʻole nā ​​ʻeha kaumaha. Ua hōʻike ʻia nā noiʻi hou ʻana he nui ka poʻe me ka ʻeha mau, ka poʻe ʻelemākule a me nā diabetic i lawa ka lawa ʻole o kēia mau wikamina i loko o ko lākou koko. ʻO kēia kekahi o nā kumu i hiki ʻole i kēia poʻe ke mālama ʻia me nā painkillers wale nō; pono lākou

ʻoi aku ma mua o kēlā. Kākoʻo ka PEA a me nā huaʻai B i nā ʻōnaehana a me nā ʻōnaehana pale i nā maʻi ʻehaʻeha.

ʻO Palmitoylethanolamide kekahi cannabinoid?

ʻO CBD (Cannabidiol) kahi pūpū i hoʻoili ʻia mai ka hemp a me ka mariuana. ʻOiai e hana maoli ke kino i ka cannabinoids maoli, ua hoʻonui ʻia ka CBD e hālāwai me ka pono.

ʻO ka Cannabinoids ka lāʻau ola olakino e hoʻoili ʻia i loko o ke kino ke kuleana no ka hoʻomanaʻo, ka ʻeha, ka momona, a me ka neʻe ʻana. Kuhi ka poʻe ʻepekema ʻoi paha ka pōmaikaʻi o nā cannabinoids i ka hōʻemi ʻana i ka mumū a me ke kaumaha, hoʻopau i nā ʻōpū aʻopa, e hāʻawi ana i ka hoʻomaha ma nā ʻūʻī a hoʻonui pū kekahi.

ʻO PEA kahi momona ʻo amide momona i hana ʻia i loko o ke kino a hiki ke kapa ʻia i kahi cannabimimetic. Kuhi kēia e hoʻowalewale i ka hana a CBD i kou kino.

Hana pololei ʻole ʻo CBD a me PEA ma ka pāpā ʻana i ka fatty acid amide hydrolase (FAAH), ka mea maʻamau breakdown anandamide a hoʻonāwaliwali iā ia. Loaʻa kēia i nā pae kiʻekiʻe o anandamide. Anandamide hana nui i ke ʻano a me ka hoʻoikaika pū kekahi. Hoʻoikaika ka pae hoʻonui o ka anandamide i ka hopena o ka ʻōnaehana endocannabinoid.

Ua loaʻa ka kaulana o PEA a hoʻokūkū me CBD. Ua ʻike ʻia ʻo PEA he wahi palekana hou no ka CBD ma muli o nā pilikia kānāwai e kū ana ma ia a me ka mea ʻo ka hapa nui o ka poʻe ʻaʻole hiki ke ʻae i ka kiʻekiʻe o ka 'pōhaku' e hele mai ana me ka CBD.

Eia hou, ʻoi aku ka maikaʻi o ka PEA ma mua o CBD. Eia nō naʻe, hiki ke hoʻohana ʻia ka PEA me ka CBD e loaʻa ai nā hopena synergetic.

ʻO Pea kahi endocannabinoid?

NO, Palmitoylethanolamide (PEA) kahi mea uwao lipid like endocannabinoid me nā analgesic a me nā anti-inflammatory waiwai. Kākoʻo ʻo PEA i ka ECS ma o ka hoʻopili ʻana i ka hōʻailona endocannabinoid a me ka hoʻoulu ʻole ʻana i nā mea loaʻa nā cannabinoid.

ʻO ka ʻōnaehana endocannabinoid (ECS) kahi ʻōnaehana biolo nui e hoʻoponopono a kaulike i ka nui o nā hana physiological i ke kino. Ua alakaʻi ʻia ka noiʻi ʻana ma ka ECS i ka endocannabinoids ʻaʻole e like me anandamide (AEA) a me 2-arachidonoylglycerol (2-AG), akā ʻo nā mea hoʻopulapula lipid like endocannabinoid e like me palmitoylethanolamide (PEA). ʻO kēia mau pūhui endocannabinoid e like me ka mahele pinepine i nā ala metabolic like o endocannabinoids akā nele ka pili paʻa no ka receptor type 1 a me ka type 2 (CB1 a me CB2).

Palmitoylethanolamide (PEA) a me Anandamide

ʻO Palmitoylethanolamide a me ka anandamide e pili pono ana no ka mea ʻelua lāua i ka hopena o ka momona acid endogenous i kūkulu ʻia i loko o ke kino.

ʻO ka PEA a me ka anandamide i ʻōlelo ʻia he hopena synergistic i ka mālama ʻana i ka ʻeha a hoʻonui pū i nā mea pepehi ʻeha i hoʻohana ʻia.

Ua wāwahi ʻia lākou hoʻi e ka enzyme hydrolase fatty acid i loko o ke kino, no laila e loaʻa nā hopena i ka wā e hoʻohana ʻia ai ʻoi aku ka nui ma mua o ka wā i hoʻohana ʻia ma ka supplemental tūlealone.

ʻO Palmitoylethanolamide VS Phenylethylamine

ʻO Phenethylamine kahi waiwai kūlohelohe e kū maoli ana e ke kino. Hoʻohana nui ʻia no ka hoʻomaikaʻi ʻana i ka hana hōʻeuʻeu a hiki iā ia hoʻi ke kōkua i ka hōʻoluʻolu o ke kaumaha, kōkua i ke kaupaona ʻana a hoʻolōʻihi i ke ʻano.

ʻO Palmitoylethanolamide ma kekahi ʻaoʻao, he fatty acid amide e ʻike nui ʻia no ka hōʻeha a me ka ʻeha.

ʻAʻole pili kēia mau mea ʻelua. ʻO ka mea wale nō e hoʻopili aku iā lāua a ua pāleania ʻia ka PEA.

Pehea wau e lawe ai i ka Palmitoylethanolamide (PEA) supplement?

ʻOiai mākou i hoʻomaikaʻi no ka pōmaikaʻi anti-inflammatory ka palmitoylethanolamide ma waena o nā pōmaikaʻi ʻē aʻe, he mea kūpono e lawe i kou nānā i kekahi mau ʻike hou e pili ana i ka PEA. ʻIke ʻia ka PEA ma nā ʻāpana nui a ʻaʻole kō i piha i ka wai, hana kēia palapala ma ka palmitoylethanolamide me ka palena o ka hoʻopili ʻana.

ʻO ka nūhou maikaʻi, ʻo ia ka mea e ʻimi nā mea hana i nā pahuhopu e hoʻonui ai i ka bioavailability palmitoylethanolamide no ka hoʻohana ʻana i ka hoʻohana nui i loko o kou kino. No kēia, Pauka PEA loaʻa i ka pauka maʻamau a me ka palapala pauka micromized.

Ma hea e kūʻai ai i ka pauka Palmitoylethanolamide (PEA)?

Aia mākou i kahi wā hoihoi kahi o nā hale kūʻai pūnaewele i lilo i hale kū hoʻokahi no nā mea āpau e like me nā lako nui o palmitoylethanolamide. Inā ʻoe e noʻonoʻo e lawe iā PEA, e noiʻi ākea no legit palmitoylethanolamide mea hoʻonui mea hoʻonui. ʻO ka hapa nui o nā mea hoʻohana o palmitoylethanolamide e kūʻai iā ia mai nā hale kūʻai pūnaewele a pono e noʻonoʻo i kā lākou loiloi no ka pauka PEA maikaʻi loa ma ka mākeke.

ailona

AEA: Anandamide

CB1: Cannabinoid type I receptor

CB2: Cannabinoid ʻano II receptor

KĀLĀWAI: Kakau Kālā Cochrane o nā hoʻāʻo i kāohi ʻia

FAAH: hydrolase amide-acid amide hydrolase

NAAA: N-acylethanolamine hydrolyzing acid amidase

NAE: N-acylethanolamines

PEA: Palmitoylethanolamid

PPARα: alpha receptor activated peroxisome proliferator

PRISMA-P: Nā mea hōʻike i makemake ʻia no nā hōʻike ʻōnaehana a me nā Meta-Analysis Protocols

VAS Pain: Nānā Analog ʻImi no ka Paʻi

ECS: ʻōnaehana endocannabinoid

Reference:

[1] Artukoglu BB, Beyer C, Zuloff-Shani A, et al. Ka maikaʻi o ka palmitoylethanolamide no ka ʻeha: kahi meta-analysis. Kauka Lapaʻau 2017; 20 (5): 353-362.

[2] Schifilliti C, Cucinotta L, Fedele V, et al. ʻO ka micronized palmitoylethanolamide e hoʻoliʻiliʻi i nā ʻōuli o ka ʻeha neuropathic i nā mea maʻi diabetic. Hana Hana ʻeha 2014; 2014: 849623.

[3] Keppel Hasselink JM, Hekker TA. ʻO ka pono therapeutic o palmitoylethanolamide i ka mālama ʻana i ka ʻeha neuropathic e pili ana i nā ʻano pathological: he hihia hihia. ʻO J Pain Res 2012; 5: 437-442.

[4] Keppel Hasselink JM, Kopsky DJ. ʻO ka hana o palmitoylethanolamide, kahi autacoid, i ka hoʻomaʻamaʻa simptomatik o nā puʻupuʻu puʻupuʻu: ʻekolu mau hōʻike hihia a me ka loiloi o nā puke. ʻO J Clin Case Rep 2016; 6 (3).

[5] ʻO Costa B, Colombo A, Bettoni I, Bresciani E, Torsello A, Comelli F. Hoʻomaha ʻo ka ligand palmitoylethanolamide endogenous i ka ʻeha neuropathic ma o ka mast cell a me ka microglia modulation. 21st Symposium Makahiki O ka International Cannabinoid Research Society. St. Charles, Il. Usa: Holo ʻo Pheasant; 2011.